BRIDGEWATER, N.J., Nov. 4, 2019 /PRNewswire/ -- Children and adolescents (aged 6 to 17 years) living with type 1 diabetes achieved comparable reduction in average blood sugar (HbA1c) and similar risk of low blood sugar events with Toujeo® (insulin glargine injection) 300 Units/mL compared to insulin glargine 100 Units/mL (Gla-100), accordin

PRINCETON, N.J., Nov. 4, 2019 /PRNewswire/ -- healtheo360, a caring social network platform for patients living with chronic, terminal, and rare health conditions has appointed Robert Cecere as its Chief Growth Officer.  Bob, a recognized sales and marketing leader in business development and digital media within healthcare and pharma, will be

LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided a corporate update and reported financial results for the third quarter of 2019.

DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new data from its ARTISTRY clinical development program related to ALKS 4230, an i

HOLON, ISRAEL, Nov. 4, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that the U.S. Food and Drug Administration has cleared its investigational new drug (IND) application fo

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced strategic actions to reposition the Company with a focus solely on its ENHANZE® drug delivery technology. In order to implement this strategic shift, Halozyme will immediately initiate an organizational restructuring to halt development a

SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. The treatment arm of PEGPH20 in combinatio

SAN CLEMENTE, Calif., Nov. 4, 2019 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, announced today that it has entered into a definitive agreement to acquire Pursuit Vascular, Inc. for $75M with an a

LOS ANGELES, Nov. 4, 2019 /PRNewswire/ -- MAX BioPharma, Inc. (www.maxbiopharma.com) recently published two articles describing its anti-tumorigenic oxysterol lead compounds in

CHICAGO, Nov. 4, 2019 /PRNewswire/ -- The Alzheimer's Association and CVS Health announced today a three-year corporate partnership aimed at fighting Alzheimer's disease – a disease impacting more than 5 million Americans and 16 million caregivers across the country. The partnership is launching with an in-store fundraising campaign that will provid